Pyxis Oncology (PYXS) Income from Continuing Operations (2020 - 2025)
Pyxis Oncology (PYXS) reported Income from Continuing Operations of 18120000.0 for Q4 2025, up 49.06% year-over-year from 12156209.12 in Q4 2024, and up 17.65% quarter-over-quarter from 22003000.0 in Q3 2025.
Pyxis Oncology (PYXS) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Income from Continuing Operations data on file, last reported at 18120000.0 in Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 18120000.0, up 49.06% year-over-year; the trailing twelve-month figure through Dec 2025 was 79867000.0 (down 0.57% YoY), and the FY2025 annual result was 79635000.0, down 2.98% from the prior year.
- Income from Continuing Operations grew to 18120000.0 in Q4 2025 per PYXS's latest filing, from 22003000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 5343000.0 in Q1 2024 and troughed at 36101000.0 in Q4 2022.
- A 5-year average of 21293450.0 and a median of 20545500.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations sank 330.7% in 2022, then jumped 73.13% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 16419000.0 in 2021, then slumped by 119.87% to 36101000.0 in 2022, then surged by 55.2% to 16173000.0 in 2023, then plunged by 119.94% to 35571000.0 in 2024, then jumped by 49.06% to 18120000.0 in 2025.
- Business Quant data shows PYXS's Income from Continuing Operations at 18120000.0 in Q4 2025, 22003000.0 in Q3 2025, and 18071000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -18.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.12 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Jun 30, 2025 | -18.07 Mn |
| Mar 31, 2025 | -21.67 Mn |
| Dec 31, 2024 | -35.57 Mn |
| Sep 30, 2024 | -21.20 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -5.34 Mn |
| Dec 31, 2023 | -16.17 Mn |
| Sep 30, 2023 | -23.65 Mn |
| Jun 30, 2023 | -16.47 Mn |
| Mar 31, 2023 | -19.89 Mn |
| Dec 31, 2022 | -36.10 Mn |
| Sep 30, 2022 | -27.67 Mn |
| Jun 30, 2022 | -25.56 Mn |
| Mar 31, 2022 | -31.38 Mn |
| Dec 31, 2021 | -16.42 Mn |
| Sep 30, 2021 | -11.62 Mn |
| Jun 30, 2021 | -5.94 Mn |
| Mar 31, 2021 | -35.73 Mn |